Tempus AI (NASDAQ:TEM) CFO James William Rogers Sells 11,529 Shares

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 11,529 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $55.00, for a total value of $634,095.00. Following the sale, the chief financial officer owned 114,866 shares in the company, valued at $6,317,630. This trade represents a 9.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James William Rogers also recently made the following trade(s):

• On Tuesday, May 19th, James William Rogers sold 10,853 shares of Tempus AI stock. The shares were sold at an average price of $44.07, for a total value of $478,291.71.

Tempus AI Stock Performance

NASDAQ TEM opened at $57.93 on Wednesday. The business’s 50-day moving average price is $50.19 and its 200 day moving average price is $54.68. Tempus AI, Inc. has a twelve month low of $41.73 and a twelve month high of $104.32. The company has a market capitalization of $10.40 billion, a PE ratio of -33.68 and a beta of 3.62. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same period last year, the company earned ($0.24) EPS. The firm’s quarterly revenue was up 36.1% on a year-over-year basis. On average, research analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: One analyst-style article argued Tempus AI remains attractive because of strong diagnostics momentum, expanding AI platform adoption, and recent FDA-related product expansion that could broaden its addressable market. Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion
• Positive Sentiment: Another article highlighted that Tempus AI’s recent pullback may have created a potential buying opportunity, suggesting some investors see value after the decline. Tempus AI stock faces a make-or-break moment after its recent pullback
• Neutral Sentiment: Konica Minolta completed the sale of Tempus shares it received in a prior transaction. This is not a direct operating update, but it removes a potential overhang from an outside holder. Konica Minolta Completes Sale of Tempus Shares to Bolster Balance Sheet
• Neutral Sentiment: Tempus also had a financial review and comparison coverage piece, but it did not include a major new company-specific catalyst. Financial Review: Tempus AI (NASDAQ:TEM) & Nyxoah (NASDAQ:NYXH)
• Negative Sentiment: Biovica said it is refocusing its U.S. commercial strategy and terminating its agreement with Tempus AI, which could signal a lost partnership or reduced commercial opportunity. Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI
• Negative Sentiment: Tempus disclosed insider selling by CFO James William Rogers and Director Jennifer A. Doudna, which can weigh on investor sentiment even though both sales were made under pre-arranged trading plans. Tempus AI (NASDAQ:TEM) CFO James William Rogers Sells 11,529 Shares of Stock Tempus AI (NASDAQ:TEM) Director Sells 2,673 Shares of Stock

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently bought and sold shares of the business. Royal Bank of Canada lifted its position in Tempus AI by 201.2% during the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock valued at $1,253,000 after buying an additional 17,359 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Tempus AI in the 1st quarter valued at $116,000. Prudential Financial Inc. purchased a new position in shares of Tempus AI in the 2nd quarter valued at $276,000. Russell Investments Group Ltd. lifted its holdings in shares of Tempus AI by 21.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock valued at $415,000 after acquiring an additional 1,146 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Tempus AI by 2,926.6% during the 2nd quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock valued at $13,446,000 after acquiring an additional 204,629 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Wall Street Analyst Weigh In

TEM has been the subject of several research analyst reports. Wolfe Research initiated coverage on shares of Tempus AI in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. HC Wainwright decreased their price target on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Guggenheim dropped their price objective on Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a report on Monday, March 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempus AI in a research report on Wednesday, June 17th. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $68.54.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.